← Back to search

Immunovant Inc

IMVT · NASDAQ

Biological Product (except Diagnostic) Manufacturing

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

ESG Scores

Overall ESG
5.4
Environmental
6.6
Social
4.4
Governance
4.5

Gender Diversity

Female Executives0.4519230769230769%
CEO GenderMale

Market Data

Price$39.53-0.39 (-0.98%)
Market Cap
P/E Ratio
EPS$—
52W High$—
52W Low$—
Beta